AGTC

AGTC is focused on the research and development of novel therapeutics for patients with unmet medical needs utilizing AGTC’s proprietary, non-pathogenic adeno-associated virus (AAV) delivery system. AGTC has demonstrated that this system can be used to deliver a normal form of a gene in both animals and humans thus allowing their own body to produce…

Antiva Biosciences

Antiva Biosciences is a clinical stage biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by Human Papilloma Virus (HPV) infection. These diseases include Cervical Intraepithelial Neoplasia (CIN), Anal Intraepithelial Neoplasia (AIN), and Vulvar Intraepithelial Neoplasia (VIN). The lead medicine was developed at UC San Diego in the lab of Dr. Karl…

Aptinyx

Aptinyx is a biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of neurological disorders such as neuropathic pain, traumatic brain injury, Parkinson’s Disease, and post-traumatic stress disorder (PTSD). The company is a spin-out of Naurex, a depression drug developer acquired by Allergan in 2015. The underlying work at both companies…

Arrakis Therapeutics

Arrakis is discovering and developing small molecule therapeutics that target RNA with an internal product pipeline focused on neurology, oncology, and rare genetic disorders. The basis of Arrakis’ unique approach is comprised of a high-throughput, comprehensive system of bioinformatics tools and a proprietary chemical biology technology that interrogates structures of folded RNAs in their native…

ArsenalBio

Arsenal’s novel approach can directly edit the genome of a patient’s impaired immune system cells in vitro with an automatable process that increases the breadth, accuracy, and complexity of value-added genome edits (e.g., added potency, resistance to tumor evasion, increased tumor killing, reduction in toxicity) while dramatically reducing the current standards for COGS and CAPEX,…

Artizan Biosciences

Artizan Biosciences is developing therapeutics that can eliminate disease-causing bacteria in the gut microbiome. The full write-up should be: Artizan Biosciences is developing therapeutics that can eliminate disease-causing bacteria in the gut microbiome. Artizan leverages a platform technology called IgAseq that can tag and uncover the “bad-actor” bacteria in various diseases, with an initial focus…

Atsena Therapeutics

Atsena Therapeutics is a gene therapy company that is developing novel therapies for inherited degenerative retinal diseases with no other treatment alternatives. Atsena was founded based on the research of Dr. Shannon Boye and Dr. Sanford Boye at University of Florida, who are pioneers in the field of ophthalmology gene therapy. The company is also…